Search Results

There are 119719 results for: content related to: Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies

  1. Management of chronic hepatitis C patients who have relapsed or not responded to pegylated interferon alfa plus ribavirin

    Journal of Viral Hepatitis

    Volume 16, Issue 12, December 2009, Pages: 833–843, D. T. Dieterich, M. Rizzetto and M. P. Manns

    Version of Record online : 2 NOV 2009, DOI: 10.1111/j.1365-2893.2009.01218.x

  2. Pegylated interferons for chronic hepatitis C virus infection: an indirect analysis of randomized trials

    Journal of Viral Hepatitis

    Volume 15, Issue 8, August 2008, Pages: 551–570, R. Chou, S. Carson and B. K. S. Chan

    Version of Record online : 14 MAY 2008, DOI: 10.1111/j.1365-2893.2008.00984.x

  3. An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin

    Journal of Viral Hepatitis

    Volume 19, Issue 9, September 2012, Pages: 615–622, C. Kondo, M. Atsukawa, A. Tsubota, N. Itokawa, T. Fukuda, Y. Matsushita, H. Kidokoro, T. Kobayashi, Y. Narahara, K. Nakatsuka, H. Kanazawa and C. Sakamoto

    Version of Record online : 9 FEB 2012, DOI: 10.1111/j.1365-2893.2011.01584.x

  4. Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3 infection

    Journal of Viral Hepatitis

    Volume 18, Issue 4, April 2011, Pages: 245–251, C. Pedersen, Å. Alsiö, M. Lagging, N. Langeland, M. Färkkilä, M. Rauning Buhl, K. Mørch, J. Westin, P. Sangfelt, G. Norkrans, P. Brehm Christensen and for the NORDynamicIC Study Group

    Version of Record online : 1 APR 2010, DOI: 10.1111/j.1365-2893.2010.01303.x

  5. Extended treatment duration for treatment naïve chronic hepatitis C genotype 1 late viral responders: a meta-analysis comparing 48 weeks vs 72 weeks of pegylated interferon and ribavirin

    Journal of Viral Hepatitis

    Volume 18, Issue 4, April 2011, Pages: e99–e103, M. Parikh, A. Singh and G. Sood

    Version of Record online : 18 OCT 2010, DOI: 10.1111/j.1365-2893.2010.01374.x

  6. Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin

    Journal of Viral Hepatitis

    Volume 16, Issue 8, August 2009, Pages: 586–594, N. Hiramatsu, T. Oze, T. Yakushijin, Y. Inoue, T. Igura, K. Mochizuki, K. Imanaka, A. Kaneko, M. Oshita, H. Hagiwara, E. Mita, T. Nagase, T. Ito, Y. Inui, T. Hijioka, K. Katayama, S. Tamura, H. Yoshihara, Y. Imai, M. Kato, Y. Yoshida, T. Tatsumi, K. Ohkawa, S. Kiso, T. Kanto, A. Kasahara, T. Takehara and N. Hayashi

    Version of Record online : 22 JUN 2009, DOI: 10.1111/j.1365-2893.2009.01106.x

  7. Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b

    Journal of Viral Hepatitis

    Volume 19, Issue 2, February 2012, Pages: 120–127, J. Vermehren, S. Susser, C. M. Lange, N. Forestier, U. Karey, E. Hughes, R. Ralston, X. Tong, S. Zeuzem and C. Sarrazin

    Version of Record online : 1 MAR 2011, DOI: 10.1111/j.1365-2893.2011.01449.x

  8. Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin

    Journal of Viral Hepatitis

    Volume 14, Issue 6, June 2007, Pages: 396–403, Y. Asahina, N. Izumi, N. Umeda, T. Hosokawa, K. Ueda, F. Doi, K. Tsuchiya, H. Nakanishi, K. Matsunaga, T. Kitamura, M. Kurosaki, M. Uchihara, M. Higaki and S. Miyake

    Version of Record online : 25 AUG 2006, DOI: 10.1111/j.1365-2893.2006.00803.x

  9. Genetic and biochemical diversity in the HCV NS5B RNA polymerase in the context of interferon α plus ribavirin therapy

    Journal of Viral Hepatitis

    Volume 18, Issue 5, May 2011, Pages: 349–357, F. Cao, M. J. Donlin, K. Turner, X. Cheng and J. E. Tavis

    Version of Record online : 30 MAY 2010, DOI: 10.1111/j.1365-2893.2010.01316.x

  10. Controlled release recombinant human interferon-α2b for treating patients with chronic hepatitis C genotype 1: a phase 2a clinical trial

    Journal of Viral Hepatitis

    Volume 18, Issue 4, April 2011, Pages: 271–279, I. Dzyublyk, T. Yegorova, L. Moroz, O. Popovych, I. Zaytsev, V. Miroshnichenko, A. Kromminga, M. M. Wilkes, E. J. van Hoogdalem and J. E. Humphries

    Version of Record online : 28 MAR 2010, DOI: 10.1111/j.1365-2893.2010.01298.x

  11. You have free access to this content
    Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C

    Intervention Review

    The Cochrane Library

    Goran Hauser, Tahany Awad, Jesper Brok, Kristian Thorlund, Davor Štimac, Mahasen Mabrouk, Christian Gluud and Lise Lotte Gluud

    Published Online : 28 FEB 2014, DOI: 10.1002/14651858.CD005441.pub3

  12. A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment

    Journal of Viral Hepatitis

    Volume 15, Issue 5, May 2008, Pages: 370–378, Z. M. Younossi, F. H. Nader, C. Bai, R. Sjogren, J. P. Ong, R. Collantes, M. Sjogren, D. Farmer, L. Ramsey, K. Terra, H. Gujral, C. Gurung, M. Srishord and Y. Fang

    Version of Record online : 10 JAN 2008, DOI: 10.1111/j.1365-2893.2007.00956.x

  13. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C

    Journal of Viral Hepatitis

    Volume 15, Issue 7, July 2008, Pages: 475–481, J. McHutchison and M. Sulkowski

    Version of Record online : 24 MAR 2008, DOI: 10.1111/j.1365-2893.2008.00973.x

  14. Hepatitis C therapy in non-genotype 1 patients: the near future

    Journal of Viral Hepatitis

    Volume 19, Issue 8, August 2012, Pages: 525–536, C. Wartelle-Bladou, G. Le Folgoc, M. Bourlière and L. Lecomte

    Version of Record online : 4 JUL 2012, DOI: 10.1111/j.1365-2893.2012.01634.x

  15. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C

    Journal of Viral Hepatitis

    Volume 14, Issue 10, October 2007, Pages: 721–729, A. M. Di Bisceglie, R. H. Ghalib, F. M. Hamzeh and V. K. Rustgi

    Version of Record online : 26 APR 2007, DOI: 10.1111/j.1365-2893.2007.00862.x

  16. You have free access to this content
    HCV Therapeutics: Approved Agents

    Hepatology

    Volume 58, Issue S1, October 2013, Pages: 1091A–1168A,

    Version of Record online : 15 OCT 2013, DOI: 10.1002/hep.26880

  17. IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma

    Journal of Viral Hepatitis

    Volume 18, Issue 10, October 2011, Pages: e550–e560, T. Kawaoka, H. Aikata, S. Takaki, A. Hiramatsu, K. Waki, N. Hiraga, D. Miki, M. Tsuge, M. Imamura, Y. Kawakami, S. Takahashi, H. Ochi, H. Tashiro, H. Ohdan and K. Chayama

    Version of Record online : 23 MAY 2011, DOI: 10.1111/j.1365-2893.2011.01468.x

  18. You have free access to this content
    Diagnosis, management, and treatment of hepatitis C: An update

    Hepatology

    Volume 49, Issue 4, April 2009, Pages: 1335–1374, Marc G. Ghany, Doris B. Strader, David L. Thomas and Leonard B. Seeff

    Version of Record online : 2 DEC 2008, DOI: 10.1002/hep.22759

  19. You have free access to this content
    AASLD Abstracts

    Hepatology

    Volume 56, Issue S1, October 2012, Pages: 191A–1144A,

    Version of Record online : 1 OCT 2012, DOI: 10.1002/hep.26040

  20. You have free access to this content
    Poster Sessions

    Hepatology

    Volume 58, Issue S1, October 2013, Pages: 92A–207A,

    Version of Record online : 1 OCT 2013, DOI: 10.1002/hep.26726